Abstract 3647
Background
Fixed-dose adjuvant subcutaneous (s.c.) trastuzumab (T) has been approved in the treatment of early HER2-positive breast cancer (BC), based on the evidence of its non-inferiority to standard intravenous (i.v.) infusion. Few data from real-life are available regarding cardiac toxicities associated with fixed-dose subcutaneous T administration. We conducted a retrospective study in order to compare cardiac toxicity profile of adjuvant fixed-dose s.c.-T and weight-based i.v.-T, according to anthropometric data which takes into account more than simply weight.
Methods
Patients treated with adjuvant T for HER2-positive breast cancer at Humanitas Research Hospital from December 2013 to October 2017 were evaluated. T was administered at a either fixed dose of 600 mg s.c. or 6 mg/kg i.v, respectively. Data regarding previous chemotherapy, Body Mass Index (BMI), and development of cardiotoxicity (decrease in LVEF >10% points, to a value < 50%) were extracted from medical records. Four BMI classes were considered: underweight (BMI < 18 kg/sqm), normal weight (18-24.9 kg/sqm), overweight (25-29.99), and obesity (≥30). All variables were compared with categorical tests (Pearson Chi-squared with Yates correction or Fisher exact test).
Results
A total of 260 HER2-positive BC patients receiving adjuvant T were analyzed. Median age was 56 (range, 32-88), median BMI 23.5 (range, 15.8-50.2 kg/sqm). 196 (75.38%) patients received s.c.-T and 64 (24.62%) i.v.-T. 156 had a normal weight, while 11 were underweight, 54 overweight and 39 obese. The incidence of cardiotoxicity was not different among the BMI classes according to the route of administration of T (p = 0.28). In the subset of the patients who had developed cardiac toxicity, BMI did not result as a risk factor, as well as a previous treatment with anthracyclines (p = 0.89).
Conclusions
Cardiac toxicity profile of fixed-dose s.c.-T is consistent with that of weight-based i.v.-T in the real-world setting regardless differences in anthropometric data as BMI. Our study confirms safety of subcutaneous T administration, which still represents a valid and more convenient alternative to intravenous administration.
Clinical trial identification
Legal entity responsible for the study
Istituto Clinico Humanitas.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2069 - The concordance with antiemetic guideline for pediatric, adolescent and young adult patients with cancer using a large-scale administrative database.
Presenter: Seiko Bun
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2740 - Effectiveness of surgical glove compression therapy as a prophylactic method against nab-Paclitaxel induced peripheral neuropathy
Presenter: Shigeru Tsuyuki
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2229 - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)
Presenter: Hubert Piessevaux
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4155 - Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)
Presenter: Antony Mersiades
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2473 - Pregnancies after breast cancer, is there a real need for fertility preservation ? Results from the ARTEMIS cohort of 60 young patients
Presenter: Jerome Martin-Babau
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3450 - Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: a reality or a myth?
Presenter: Aurore Vozy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2917 - Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey
Presenter: Jean-Francois Morere
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2920 - Benefits of physical activity and sport integrated into the care pathway of oncology patient
Presenter: Laurence Vanlemmens
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5334 - Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study
Presenter: Quan Tran
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
6108 - Quality of life, late effects, and related clinical factors among Korean colorectal cancer survivors
Presenter: Ji Soo Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract